Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Trial Profile

Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2010

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder; Urge incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2009 Results presented at the 39th Annual Meeting of the International Continence Society.
    • 16 May 2009 Results have been presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
    • 27 Apr 2009 Results in women have been presented at the annual conference of the American Urological Association, according to a Waston Pharmaceutical's media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top